Icatibanto Glenmark

Icatibant, the active ingredient in Icatibanto Glenmark, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibanto Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures quality control, cold‑chain logistics and compliance with global import requirements.

Icatibant is used to manage hereditary angioedema, a disorder characterized by bradykinin‑mediated swelling.

Hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces swelling during acute attacks. Hereditary angioedema type I: provides symptom relief when attacks occur. Hereditary angioedema type II: blocks bradykinin effects to control episodes.

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain or erythema. - Local swelling or induration. - Nausea or mild gastrointestinal discomfort. - Headache or dizziness. - Transient flushing. - Mild fever.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Angioedema unrelated to hereditary disease. - Severe hypotension. - Thrombocytopenia. - Urticaria or widespread rash.

Before prescribing icatibant, clinicians should consider several safety measures.

Confirm diagnosis: ensure the patient has hereditary angioedema with C1‑inhibitor deficiency. Assess hypersensitivity: avoid in individuals with known allergy to icatibant or its excipients. Monitor cardiovascular status: use cautiously in patients with unstable heart disease. Avoid concomitant ACE inhibitors: these may increase the risk of angioedema. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that affect the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may exacerbate angioedema; concurrent use should be avoided. - Other bradykinin B2 receptor antagonists: additive blockade could increase adverse effects.

Moderate Interactions (Monitor Closely): - C1‑inhibitor concentrates: may alter therapeutic response; monitor clinical outcome. - Diuretics: potential for blood pressure changes; observe patient. - Antihistamines: may mask early signs of hypersensitivity; watch for reactions.